Factor VII Activity

Clinical Significance

Limitations
Expected impact by therapeutic levels (potential interference depends upon drug concentration): Warfarin: decreased, Heparin (UFH or LMWH): no effect (reagent contains heparin neutralizer); Dabigatran or Argatroban (Thrombin Inhibitors): no effect to inhibitor pattern or falsely low; Rivaroxaban or Apixaban (Factor Xa Inhibitors): no effect to inhibitor pattern

Specimen Requirements

1.0 mL frozen platelet poor plasma from a Blue Top Tube - 3.2% Na Citrate in a Plastic Vial

Transport And Storage

Unacceptable Ambient
Unacceptable Refrigerated
14 days Frozen(Transport)

Collection Instructions

Clinical history/reason for referral is required with test order.

Centrifuge light blue-top tube for 15 minutes at approximately 1500 g within 60 minutes of collection. Using a plastic pipette, remove plasma, taking care to avoid the WBC/platelet buffy layer and place into a plastic vial. Centrifuge a second time and transfer platelet-poor plasma into a new plastic vial. Plasma must be free of platelets (<10,000/mcl). Freeze immediately and ship on dry ice.

Minimum Volume

0.5 mL Platelet Poor Plasma

Neonatal Volume

Reference Range:

60 -150% of normal

Methodology:

• Photometric Clot Detection

Clinical Significance

Limitations
Expected impact by therapeutic levels (potential interference depends upon drug concentration): Warfarin: decreased, Heparin (UFH or LMWH): no effect (reagent contains heparin neutralizer); Dabigatran or Argatroban (Thrombin Inhibitors): no effect to inhibitor pattern or falsely low; Rivaroxaban or Apixaban (Factor Xa Inhibitors): no effect to inhibitor pattern

CDM

01453627

CPT Coding

85230